Themis Medicare Limited (THEMISMED.NS)
INR 128.07
(-0.93%)
INR 128.07
(-0.93%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.3 Billion INR | -52.17% |
| 2022 | 820.79 Million INR | -4.73% |
| 2021 | 861.55 Million INR | 110.41% |
| 2020 | 409.46 Million INR | 49.14% |
| 2019 | 274.55 Million INR | 581.75% |
| 2018 | -56.99 Million INR | -131.98% |
| 2017 | 178.19 Million INR | -51.61% |
| 2016 | 368.26 Million INR | 0.4% |
| 2015 | 366.79 Million INR | 365.73% |
| 2014 | 78.75 Million INR | -47.21% |
| 2013 | 149.19 Million INR | 90.15% |
| 2012 | 78.46 Million INR | 145.07% |
| 2011 | -174.09 Million INR | -176.99% |
| 2010 | 226.12 Million INR | -22.21% |
| 2009 | 290.69 Million INR | 394.34% |
| 2008 | 58.8 Million INR | -79.92% |
| 2007 | 292.9 Million INR | 37.05% |
| 2006 | 213.72 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 267.69 Million INR | 328.98% |
| 2024 Q2 | 146.77 Million INR | -45.17% |
| 2023 Q2 | 159.95 Million INR | -36.04% |
| 2023 Q3 | 109.03 Million INR | -31.83% |
| 2023 Q4 | 62.4 Million INR | -42.77% |
| 2023 FY | 392.58 Million INR | -52.17% |
| 2023 Q1 | 250.09 Million INR | 92.38% |
| 2022 Q1 | 178.99 Million INR | 48.9% |
| 2022 Q2 | 250 Million INR | 39.67% |
| 2022 Q4 | 129.99 Million INR | -34.09% |
| 2022 Q3 | 197.24 Million INR | -21.1% |
| 2022 FY | 820.79 Million INR | -4.73% |
| 2021 Q4 | 120.2 Million INR | -19.47% |
| 2021 FY | 861.55 Million INR | 110.41% |
| 2021 Q1 | 381.22 Million INR | 286.26% |
| 2021 Q2 | 210.85 Million INR | -44.69% |
| 2021 Q3 | 149.27 Million INR | -29.21% |
| 2020 Q4 | 98.69 Million INR | -25.02% |
| 2020 Q1 | 102.57 Million INR | -9.9% |
| 2020 Q3 | 131.62 Million INR | 71.88% |
| 2020 FY | 409.46 Million INR | 49.14% |
| 2020 Q2 | 76.57 Million INR | -25.34% |
| 2019 Q3 | 72.61 Million INR | 115.55% |
| 2019 Q1 | 54.41 Million INR | 165.98% |
| 2019 Q4 | 113.84 Million INR | 56.78% |
| 2019 FY | 274.55 Million INR | 581.75% |
| 2019 Q2 | 33.68 Million INR | -38.1% |
| 2018 Q2 | 7.64 Million INR | -64.87% |
| 2018 FY | -56.99 Million INR | -131.98% |
| 2018 Q1 | 21.77 Million INR | -71.26% |
| 2018 Q3 | -3.93 Million INR | -151.41% |
| 2018 Q4 | -82.48 Million INR | -1997.74% |
| 2017 Q2 | 77.05 Million INR | 133.41% |
| 2017 Q3 | 37.61 Million INR | -51.19% |
| 2017 Q4 | 75.76 Million INR | 101.43% |
| 2017 FY | 178.19 Million INR | -51.61% |
| 2017 Q1 | 33.01 Million INR | -30.08% |
| 2016 Q1 | 98.79 Million INR | 57.17% |
| 2016 FY | 368.26 Million INR | 0.4% |
| 2016 Q4 | 47.21 Million INR | -13.28% |
| 2016 Q3 | 54.44 Million INR | -48.45% |
| 2016 Q2 | 105.6 Million INR | 6.9% |
| 2015 Q2 | 95.22 Million INR | 10.07% |
| 2015 Q1 | 86.51 Million INR | 206.33% |
| 2015 FY | 366.79 Million INR | 365.73% |
| 2015 Q4 | 62.85 Million INR | -14.17% |
| 2015 Q3 | 73.23 Million INR | -23.1% |
| 2014 Q4 | -81.36 Million INR | -237.97% |
| 2014 Q3 | 58.97 Million INR | 89.44% |
| 2014 Q1 | 61.46 Million INR | 0.0% |
| 2014 FY | 78.75 Million INR | -47.21% |
| 2014 Q2 | 31.12 Million INR | -49.35% |
| 2013 FY | 149.19 Million INR | 90.15% |
| 2012 Q3 | -13.35 Million INR | -130.96% |
| 2012 Q1 | 44.57 Million INR | 0.0% |
| 2012 FY | 78.46 Million INR | 145.07% |
| 2012 Q4 | 4.1 Million INR | 130.73% |
| 2012 Q2 | 43.13 Million INR | -3.23% |
| 2011 FY | -174.09 Million INR | -176.99% |
| 2010 FY | 226.12 Million INR | -22.21% |
| 2009 FY | 290.69 Million INR | 394.34% |
| 2008 FY | 58.8 Million INR | -79.92% |
| 2007 FY | 292.9 Million INR | 37.05% |
| 2006 FY | 213.72 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 621.02 Million INR | -109.831% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -6208.603% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 81.965% |
| FDC Limited | 3.03 Billion INR | 57.046% |
| Gufic Biosciences Limited | 2.89 Billion INR | 54.969% |
| Hikal Limited | 1.49 Billion INR | 12.789% |
| Ind-Swift Laboratories Limited | 2 Billion INR | 35.138% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | 73.633% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -526.342% |
| Medico Remedies Limited | 277.11 Million INR | -370.235% |
| Nectar Lifesciences Limited | 3.89 Billion INR | 66.506% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | -136.246% |
| RPG Life Sciences Limited | 2.29 Billion INR | 43.153% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Shilpa Medicare Limited | 3.76 Billion INR | 65.357% |
| Sigachi Industries Limited | 1.47 Billion INR | 11.588% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Venus Remedies Limited | 534.65 Million INR | -143.73% |
| Wanbury Limited | 1.7 Billion INR | 23.67% |
| ZIM Laboratories Limited | 1.09 Billion INR | -18.668% |
| Lupin Limited | 27.75 Billion INR | 95.305% |
| Innova Captab Limited | 2.53 Billion INR | 48.563% |
| Ind-Swift Limited | 1.22 Billion INR | -6.292% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 98.753% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 133.821% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | 70.873% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -4645.812% |
| Morepen Laboratories Limited | 4.17 Billion INR | 68.779% |
| Laurus Labs Limited | 3.94 Billion INR | 66.998% |
| Aarti Drugs Limited | 7.14 Billion INR | 81.771% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 85.487% |
| Alembic Limited | 767.77 Million INR | -69.726% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 77.369% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 79.96% |
| Vaishali Pharma Limited | 6.29 Million INR | -20603.924% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 58.342% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -508.814% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 74.887% |
| Eris Lifesciences Limited | 5.18 Billion INR | 74.852% |
| Windlas Biotech Limited | 1.29 Billion INR | -0.325% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 98.751% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | 31.643% |
| Orchid Pharma Limited | 2.36 Billion INR | 44.809% |
| Albert David Limited | 1.33 Billion INR | 2.349% |
| Hester Biosciences Limited | 364.77 Million INR | -257.24% |
| Sakar Healthcare Limited | 495.5 Million INR | -162.985% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 71.719% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 53.227% |
| Divi's Laboratories Limited | 18.31 Billion INR | 92.883% |
| Mankind Pharma Limited | 40.86 Billion INR | 96.811% |
| Neuland Laboratories Limited | 5.31 Billion INR | 75.497% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 82.721% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 97.129% |
| Wockhardt Limited | 140 Million INR | -830.789% |
| Bal Pharma Limited | 214.56 Million INR | -507.313% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 98.076% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -5.857% |
| Alkem Laboratories Limited | 19.46 Billion INR | 93.304% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 19.67 Billion INR | 93.378% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -448.304% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -45932.677% |
| Granules India Limited | 6.52 Billion INR | 80.039% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Ipca Laboratories Limited | 29.59 Billion INR | 95.597% |
| Brooks Laboratories Limited | -72.25 Million INR | 1903.556% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -422.808% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 94.857% |
| NATCO Pharma Limited | 25.96 Billion INR | 94.981% |
| Suven Life Sciences Limited | -1.22 Billion INR | 206.305% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 75.064% |
| Indoco Remedies Limited | 1.52 Billion INR | 14.517% |
| Alpa Laboratories Limited | 61.51 Million INR | -2018.353% |
| Lasa Supergenerics Limited | -458 Million INR | 384.518% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 131.667% |